BioServe touts the repository as the "the largest resource of high-quality biosamples for the life science industry" and claims that researchers can access it to garner biosamples from "most any major diseases."
As part of its request for dismissal, MIT admitted no wrongdoing, but agreed to be bound by any court ruling against the case's other defendants, the Whitehead Institute for Biomedical Research and the University of Massachusetts Medical School.
"I've been absolutely blown away by the microRNA field and the way it's blossomed," University of Massachusetts Medical School researcher and Nobel laureate Craig Mello said. "There is just one story after another [showing that] microRNAs … are very critical to many aspects of either disease or development."
The RTI hopes to create synergies between investigators focused on basic science researchers and those oriented towards the clinic by putting them in the same space. At the same time, the institute aims to foster research that encompasses all RNA-related pathways, not just RNAi.